View ValuationSwedencare 향후 성장Future 기준 점검 3/6Swedencare (는) 각각 연간 50.2% 및 9.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 49.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 3.6% 로 예상됩니다.핵심 정보50.2%이익 성장률49.78%EPS 성장률Pharmaceuticals 이익 성장14.5%매출 성장률9.1%향후 자기자본이익률3.61%애널리스트 커버리지Low마지막 업데이트08 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 23Swedencare AB (Publ) Approves Board ChangesSwedencare AB (publ) at its Annual General Meeting held on April 23, 2026, elected Diego Maurizio and Thomas Thomsen as board members. The Annual General Meeting decided to new elect Thomas Eklund as Chairman of the Board.공시 • Mar 26Swedencare Showcases Proden Plaqueoff Crunchy Dental Bites At Global Pet ExpoSwedencare was at Global Pet Expo in Orlando, Florida, from March 25 to 27 in booth #4401 showcasing ProDen PlaqueOff Crunchy Dental Bites. These bite-sized supplements help reduce plaque and tartar buildup while keeping breath fresh, all in a tasty, pet-approved format. Formulated with the brand's signature A.N ProDen (a 100% organic kelp sustainably harvested from pristine Scandinavian waters), these bites offer a simple and tasty way to support a healthier smile. ProDen PlaqueOff is formulated to work naturally without the need for chewing or brushing, supporting the prevention of plaque buildup and the softening of tartar. With no artificial additives, preservatives or flavors, pet parents can confidently give their pets a cleaner, healthier mouth without any unnecessary fillers. These supplements come in a tasty veggie flavor and are available in three convenient sizes: a six-ounce bag for medium and large dogs, a three-ounce bag for small dogs, and a three-ounce bag for cats. Easy to incorporate into any routine, these low-calorie bites can be given daily alongside a pet's regular dental care regimen. Plus, the dog formula is VOHC-approved for both plaque and tartar control, providing pet parents with a trusted, research-backed solution for long-term oral health.공시 • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.공시 • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.공시 • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026공시 • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026공시 • Oct 31Swedencare AB (publ), Annual General Meeting, Feb 26, 2026Swedencare AB (publ), Annual General Meeting, Feb 26, 2026.공시 • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026공시 • Apr 24+ 1 more updateSwedencare AB (Publ) Approves Election of Isabelle Guiller as DirectorSwedencare AB (publ) announced that at its AGM held on April 25, 2025, shareholders approved the election of Isabelle Guiller as director.공시 • Mar 24Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million.Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million on March 24, 2025. Under the terms of agreement, the initial purchase price is £30 million (approximately SEK 395.4 million) along with a two-year earn-out arrangement. The cash consideration will include £27 million (approximately SEK 355.9 million) drawn from available cash and RCF-credit) and an issue-in-kind of 978,119 shares in Swedencare (approximately SEK 39.5 million) to the seller upon closing, which is expected to take place on April 1, 2025. A condition-based purchase price (earn-out) of a maximum GBP 15 million (SEK 197.7 million) may be paid if certain conditions are met as of April 1, 2027. For the calendar year 2024, Summit Veterinary Pharmaceuticals Limited had revenue of £2.7 million. Post completion of the acquiistion, Summit will continue to be led by Steve Organ, the founder and former owner, for the next two years. Steve will also become a shareholder of Swedencare with 978,119 shares. Advokatfirman Lindahl KB, with the assistance of Reynolds Porter Chamberlain LLP (RPC) acted as legal advisor to Swedencare. Lincoln International acted as exclusive financial advisor to Summit UK for the transaction. Redfern acted as exclusive legal advisor to Summit UK for the transaction. Swedencare AB (publ) (OM:SECARE) completed the acquisition of Summit Veterinary Pharmaceuticals Limited on March 24, 2025.공시 • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026공시 • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025공시 • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025공시 • Nov 20Swedencare AB (publ) to Report Q4, 2024 Results on Mar 11, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results at 9:00 AM, Central European Standard Time on Mar 11, 2025공시 • Nov 15Swedencare AB (publ), Annual General Meeting, Apr 24, 2025Swedencare AB (publ), Annual General Meeting, Apr 24, 2025.공시 • Aug 23+ 1 more updateSwedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025Swedencare AB (publ) announced that they will report Q2, 2025 results on Jul 24, 2025공시 • Apr 26+ 2 more updatesSwedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results on Feb 13, 2025공시 • Nov 17Swedencare AB (Publ) Announces Nomination Committee AppointmentsSwedencare AB (publ) appointed a nomination committee for the Annual General Meeting on April 25th, 2024. The Nomination Committee consists of the following persons: Håkan Svanberg, appointed by Håkan Svanberg & Co Health Care AB, Chairman of the Nomination Committee, Heinz-Juergen Bertram, appointed by Symrise AG, Anna Magnusson, appointed by Första AP-fonden.공시 • Oct 26+ 3 more updatesSwedencare AB (publ), Annual General Meeting, Apr 25, 2024Swedencare AB (publ), Annual General Meeting, Apr 25, 2024.공시 • Jun 07Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billionSymrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion on June 5, 2023. Under the terms, SEK 37.50 per share in cash will be acquired for 111,112,282 shares. The consideration payable in respect of the Offer is financed in full by available funds and existing credit facilities. Completion of the Offer is conditional upon the Offer and the acquisition of Swedencare receiving all necessary regulatory, governmental or similar clearances, approvals and decisions, including approvals and clearances, competition authorities and Swedencare's board approval. The acceptance period for the Offer commences on June 21, 2023 and expires on July 26, 2023. Skandinaviska Enskilda Banken AB acted as financial advisor and Advokatfirman Vinge as legal advisor to Symrise AG.공시 • Feb 17+ 1 more updateSwedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 final results on Apr 06, 2023공시 • Feb 16+ 1 more updateSwedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023Swedencare AB (publ) announced that they will report first half, 2023 results on Jul 27, 2023공시 • Feb 11Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023이익 및 매출 성장 예측OTCPK:SWDC.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20283,411307555584312/31/20273,124228476496312/31/20262,85314638740133/31/20262,70049244295N/A12/31/20252,69156276327N/A9/30/20252,67563313364N/A6/30/20252,60365292337N/A3/31/20252,58293310385N/A12/31/20242,53699288359N/A9/30/20242,50462338404N/A6/30/20242,47276351414N/A3/31/20242,41472381415N/A12/31/20232,33859408444N/A9/30/20232,20887410444N/A6/30/20232,08553332376N/A3/31/20231,98797257314N/A12/31/20221,84395193260N/A9/30/20221,6009896170N/A6/30/20221,33510569135N/A3/31/20221,01960114161N/A12/31/20217735598126N/A9/30/20216184090106N/A6/30/2021465447479N/A3/31/2021337344548N/A12/31/2020240333637N/A9/30/2020174342629N/A6/30/2020136282831N/A3/31/2020134302024N/A12/31/201912730N/A33N/A9/30/201912130N/A32N/A6/30/201911328N/A30N/A3/31/201910827N/A28N/A12/31/20189923N/A22N/A9/30/20189423N/A21N/A6/30/20189220N/A15N/A3/31/20188517N/A14N/A12/31/20178617N/A13N/A9/30/20177812N/A4N/A6/30/20177011N/A4N/A3/31/20176312N/A4N/A12/31/20165410N/A2N/A9/30/2016439N/A8N/A6/30/2016378N/A9N/A3/31/2016348N/A5N/A12/31/2015277N/A4N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SWDC.F 의 연간 예상 수익 증가율(50.2%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: SWDC.F 의 연간 수익(50.2%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SWDC.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: SWDC.F 의 수익(연간 9.1%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SWDC.F 의 수익(연간 9.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SWDC.F의 자본 수익률은 3년 후 3.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 07:30종가2026/03/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Swedencare AB (publ)는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Johan BrownABG Sundal Collier SponsoredAdela DashianJefferies LLCAdrian ElmlundNordea Markets1명의 분석가 더 보기
공시 • Apr 23Swedencare AB (Publ) Approves Board ChangesSwedencare AB (publ) at its Annual General Meeting held on April 23, 2026, elected Diego Maurizio and Thomas Thomsen as board members. The Annual General Meeting decided to new elect Thomas Eklund as Chairman of the Board.
공시 • Mar 26Swedencare Showcases Proden Plaqueoff Crunchy Dental Bites At Global Pet ExpoSwedencare was at Global Pet Expo in Orlando, Florida, from March 25 to 27 in booth #4401 showcasing ProDen PlaqueOff Crunchy Dental Bites. These bite-sized supplements help reduce plaque and tartar buildup while keeping breath fresh, all in a tasty, pet-approved format. Formulated with the brand's signature A.N ProDen (a 100% organic kelp sustainably harvested from pristine Scandinavian waters), these bites offer a simple and tasty way to support a healthier smile. ProDen PlaqueOff is formulated to work naturally without the need for chewing or brushing, supporting the prevention of plaque buildup and the softening of tartar. With no artificial additives, preservatives or flavors, pet parents can confidently give their pets a cleaner, healthier mouth without any unnecessary fillers. These supplements come in a tasty veggie flavor and are available in three convenient sizes: a six-ounce bag for medium and large dogs, a three-ounce bag for small dogs, and a three-ounce bag for cats. Easy to incorporate into any routine, these low-calorie bites can be given daily alongside a pet's regular dental care regimen. Plus, the dog formula is VOHC-approved for both plaque and tartar control, providing pet parents with a trusted, research-backed solution for long-term oral health.
공시 • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
공시 • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
공시 • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026
공시 • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026
공시 • Oct 31Swedencare AB (publ), Annual General Meeting, Feb 26, 2026Swedencare AB (publ), Annual General Meeting, Feb 26, 2026.
공시 • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
공시 • Apr 24+ 1 more updateSwedencare AB (Publ) Approves Election of Isabelle Guiller as DirectorSwedencare AB (publ) announced that at its AGM held on April 25, 2025, shareholders approved the election of Isabelle Guiller as director.
공시 • Mar 24Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million.Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million on March 24, 2025. Under the terms of agreement, the initial purchase price is £30 million (approximately SEK 395.4 million) along with a two-year earn-out arrangement. The cash consideration will include £27 million (approximately SEK 355.9 million) drawn from available cash and RCF-credit) and an issue-in-kind of 978,119 shares in Swedencare (approximately SEK 39.5 million) to the seller upon closing, which is expected to take place on April 1, 2025. A condition-based purchase price (earn-out) of a maximum GBP 15 million (SEK 197.7 million) may be paid if certain conditions are met as of April 1, 2027. For the calendar year 2024, Summit Veterinary Pharmaceuticals Limited had revenue of £2.7 million. Post completion of the acquiistion, Summit will continue to be led by Steve Organ, the founder and former owner, for the next two years. Steve will also become a shareholder of Swedencare with 978,119 shares. Advokatfirman Lindahl KB, with the assistance of Reynolds Porter Chamberlain LLP (RPC) acted as legal advisor to Swedencare. Lincoln International acted as exclusive financial advisor to Summit UK for the transaction. Redfern acted as exclusive legal advisor to Summit UK for the transaction. Swedencare AB (publ) (OM:SECARE) completed the acquisition of Summit Veterinary Pharmaceuticals Limited on March 24, 2025.
공시 • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026
공시 • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025
공시 • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025
공시 • Nov 20Swedencare AB (publ) to Report Q4, 2024 Results on Mar 11, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results at 9:00 AM, Central European Standard Time on Mar 11, 2025
공시 • Nov 15Swedencare AB (publ), Annual General Meeting, Apr 24, 2025Swedencare AB (publ), Annual General Meeting, Apr 24, 2025.
공시 • Aug 23+ 1 more updateSwedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025Swedencare AB (publ) announced that they will report Q2, 2025 results on Jul 24, 2025
공시 • Apr 26+ 2 more updatesSwedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results on Feb 13, 2025
공시 • Nov 17Swedencare AB (Publ) Announces Nomination Committee AppointmentsSwedencare AB (publ) appointed a nomination committee for the Annual General Meeting on April 25th, 2024. The Nomination Committee consists of the following persons: Håkan Svanberg, appointed by Håkan Svanberg & Co Health Care AB, Chairman of the Nomination Committee, Heinz-Juergen Bertram, appointed by Symrise AG, Anna Magnusson, appointed by Första AP-fonden.
공시 • Oct 26+ 3 more updatesSwedencare AB (publ), Annual General Meeting, Apr 25, 2024Swedencare AB (publ), Annual General Meeting, Apr 25, 2024.
공시 • Jun 07Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billionSymrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion on June 5, 2023. Under the terms, SEK 37.50 per share in cash will be acquired for 111,112,282 shares. The consideration payable in respect of the Offer is financed in full by available funds and existing credit facilities. Completion of the Offer is conditional upon the Offer and the acquisition of Swedencare receiving all necessary regulatory, governmental or similar clearances, approvals and decisions, including approvals and clearances, competition authorities and Swedencare's board approval. The acceptance period for the Offer commences on June 21, 2023 and expires on July 26, 2023. Skandinaviska Enskilda Banken AB acted as financial advisor and Advokatfirman Vinge as legal advisor to Symrise AG.
공시 • Feb 17+ 1 more updateSwedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 final results on Apr 06, 2023
공시 • Feb 16+ 1 more updateSwedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023Swedencare AB (publ) announced that they will report first half, 2023 results on Jul 27, 2023
공시 • Feb 11Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023